The updated guideline covers diagnosis and treatment of ADHD in children, adolescents, and adults. In all age groups, diagnosis is based on typical core symptoms (inattention, hyperactivity, impulsivity), and functional impairment in the course of person’s life. Psychiatric comorbidity is common, and must be taken into account.
Treatment should be tailored individually to include psychoeducation, psychosocial interventions and support, and/or medication. Depending on age, collaboration with family, day-care/school, and primary/occupational health care should be considered. Evidence-based and licensed drug treatments for ADHD are atomoxetine, lisdexamfetamine, methylphenidate, and, for children and adolescents, guanfacine.